Company intelligence / Profile preview

New Haven Pharmaceuticals

North Haven, Connecticut, United Stateslinkedin.com ↗

Ownership: Private
Employees: ~10
Development stage: Other

Overview

New Haven Pharmaceuticals developed DURLAZA, the first FDA-approved prescription extended-release low-dose aspirin for secondary prevention of stroke and acute cardiac events. Clinical data demonstrated that DURLAZA provides sustained antiplatelet effects over a full day. The company also advanced proprietary zinc salt-based therapies targeting gastroesophageal reflux disease, including a combination product with DURLAZA. As of the latest available information, the company appears to be inactive or closed.

Therapeutic areas: GastroenterologyCardiovascular
Modalities: Small moleculeProprietary oral controlled-release formulationsZinc salts-based therapies
Industry: Biotech

Partnerships

Yale University (technology licensing)

Beyond the preview

Go deeper on New Haven Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on New Haven Pharmaceuticals.

Explore the full profile